11:31am Monday 23 October 2017

New Insights into Why the Immune System Fails to See Cancer

Cancer hides in plain sight of the immune system. The body’s natural tumor surveillance programs should be able to detect and attack rogue cancer cells when they arise, and yet when cancer thrives, it does so because these defense systems have failed. A team of investigators led by Niroshana Anandasabapathy, MD, PhD, at Brigham and Women’s Hospital have uncovered a critical strategy that some cancers may be using to cloak themselves – they find evidence of this genetic program across 30 human cancers of the peripheral tissue, including melanoma skin cancer. Their results are published June 29 in Cell.

“Our study reveals a new immunotherapy target and provides an evolutionary basis for why the immune system may fail to detect cancers arising in tissues,” said corresponding author Anandasabapathy, of BWH’s Department of Dermatology. “The genetic program we report on helps the immune system balance itself. Parts of this program prevent the immune system from destroying healthy organs or tissues, but might also leave a blind spot for detecting and fighting cancer.”

The authors studied immune mononuclear phagocytes – a group of disparate cells that act as the “Pac man” of the immune system. When these cells detect foreign invaders and dying normal tissues, they devour or engulf their components. These cells then present these components on their surface teach T cells to maintain tolerance to healthy tissues, or to fight infections and pathogens. Despite differences in function, all immune mononuclear phagocytes found in the skin- (a peripheral tissue like lung and gut) share a common set of genetic programming, which is further enhanced when they enter the tissue. This program is conserved in fetal and adult development, and across species. And, the research team reports, is co-opted by multiple human cancers of tissue.

The team finds that this program is prompted by an “instructive cue” from interferon gamma – a molecule that plays a critical role in regulating immunity. The authors find IFN-g for mononuclear phagocytes in development but that IFN-g and tissue immune signatures are much higher in skin cancer than in healthy skin. Having an immune response measured by IFN-g and tissue signatures correlated with improved metastatic melanoma survival outcomes, making these signatures potential biomarkers for cancer survival.

The authors reasoned such a program might contain key molecules that help the immune system reduce inflammation, but that might also leave a blind spot to cancer detection. One of the key genes the researchers detected is suppressor of cytokine signaling 2 (SOCS2). When this gene was turned off in a mouse model, the immune system was able to robustly detect and reject cancer in models of melanoma and thymoma (cancer of the thymus). They also observed improved vaccination responses, and heightened auto-inflammation suggesting this gene normally dampens auto-inflammatory responses and contracts protective immunity.

“Our research suggests that these cancers are co-opting tissue-specific immune development to escape detection, but we see that turning off SOCS2 unmasks them,” said Anandasabapathy. “This sheds new light on our understanding of how the immune system is programed to see cancers and also points the way toward new therapeutic targets for treating cancers that have these signatures.”

This project was made possible through open collaborations between researchers from BWH, Princeton University, Rockefeller University, the Icahn School of Medicine at Mount Sinai, and the Broad Institute of MIT and Harvard.

This work was supported by a 5T32AR007098, Dermatology Training Grant; the DFCI Wong Family Award for Translational Cancer Research; a T32GM07739 MSTP Grant; the Searle Scholars Program; the Beckman Young Investigator Program;the NIH New Innovator Award DP2OD020839; the Melanoma Research Alliance- BWH Department of Dermatology combined grant; the Cancer Research Institute; the Klarman Family Foundation; the National Institute of Arthritis and Musculoskeletal and Skin Disease R01AR070234 and K23 AR063461.  Aviv Regev is on the SAB for ThermoFisher Scientific, Syros Pharmaceuticals and Driver Group. James Krueger is a consultant for Biogen. Levi Garraway was a consultant for Foundation Medicine, Novartis, Boehringer Ingelheim, Eli Lilly; an equity holder in Foundation Medicine; and a member of the Scientific Advisory Board at Warp Drive. Garraway also received grant support from Novartis. He is now an employee of Eli Lilly and Company.

Paper cited: Nirschl CJ et al. “IFNg-dependent tissue immune homeostasis is co-opted in the tumor microenvironment” Cell DOI: 10.1016/j.cell.2017.06.016

 Brigham and Women’s Hospital


Share on:
or:

Health news